Literature DB >> 15889252

Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain.

Guo Xiaoling1, Liu Ying, Liu Jing, Li Huifang, Zhu Xia, Fan Qingqing, Zhu Ping.   

Abstract

The variable domain of immunoglobulin heavy chain (Ig HV) is well-characterized tumor associated antigen expressed in B-cell malignancies, which may function as a T-cell target. However, T-cell epitopes derived from shared framework regions (FRs) of each IgHV subfamily capable of inducing cytotoxic T lymphocytes (CTLs) against the B-cell malignancy, have not been identified. Using the specific PCR primers of seven IgHV gene subfamilies, we amplified the IgHV gene rearrangement for 108 cases of B-cell acute lymphoblastic leukemia (B-ALL) patients. The IgHV gene rearrangement fragments of B-ALL patients were directly sequenced then classified into seven different subfamilies. The T-cell epitopes encoded by the IgHV gene in the B-ALL patients were predicted by SYFPEITHI and BIMAS programs and compared with those from 56 representative germline IgHV sequences in the genebank. For the HLA-A*0201 locus, we found 1 or 2 top score shared epitopes from each subfamily and got 12 epitopes altogether. Results showed that ten of them were in the FRs. Using an antigen-specific T-cell expansion system, we generated the peptide-special CTLs in vitro, which were capable of killing B lymphoma cell lines that belonged to the same IgHV subfamily in a peptide-specific and HLA-restricted manner. Furthermore, we proved that the cytotoxicity of CTLs was IgHV subfamily-specific. These data indicate possible immunotherapy approaches for B-cell malignances patients based on IgHV gene subfamilies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889252     DOI: 10.1007/s00262-005-0696-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  4 in total

1.  Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells.

Authors:  Jinsheng Weng; Flavio Egidio Baio; Kelsey E Moriarty; Hiroki Torikai; Hua Wang; Zhiqiang Liu; Sourindra N Maiti; Dongho Gwak; Michael S Popescu; Soung-Chul Cha; Laurence J N Cooper; Sattva S Neelapu; Larry W Kwak
Journal:  Oncoimmunology       Date:  2016-09-19       Impact factor: 8.110

Review 2.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 3.  Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

Authors:  Elena Muraro; Debora Martorelli; Riccardo Dolcetti
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

4.  B-cell lymphomas present immunoglobulin neoantigens.

Authors:  Michael S Khodadoust; Niclas Olsson; Binbin Chen; Brian Sworder; Tanaya Shree; Chih Long Liu; Lichao Zhang; Debra K Czerwinski; Mark M Davis; Ronald Levy; Joshua E Elias; Ash A Alizadeh
Journal:  Blood       Date:  2018-12-13       Impact factor: 25.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.